SG11201503042QA - Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections - Google Patents
Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infectionsInfo
- Publication number
- SG11201503042QA SG11201503042QA SG11201503042QA SG11201503042QA SG11201503042QA SG 11201503042Q A SG11201503042Q A SG 11201503042QA SG 11201503042Q A SG11201503042Q A SG 11201503042QA SG 11201503042Q A SG11201503042Q A SG 11201503042QA SG 11201503042Q A SG11201503042Q A SG 11201503042QA
- Authority
- SG
- Singapore
- Prior art keywords
- amino
- treatment
- viral infections
- quinazoline derivatives
- heterocyclic substituted
- Prior art date
Links
- 208000036142 Viral infection Diseases 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 title 1
- CZAAKPFIWJXPQT-UHFFFAOYSA-N quinazolin-2-amine Chemical class C1=CC=CC2=NC(N)=NC=C21 CZAAKPFIWJXPQT-UHFFFAOYSA-N 0.000 title 1
- 230000009385 viral infection Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12192970 | 2012-11-16 | ||
| PCT/EP2013/073901 WO2014076221A1 (en) | 2012-11-16 | 2013-11-15 | Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201503042QA true SG11201503042QA (en) | 2015-06-29 |
Family
ID=47189782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201503042QA SG11201503042QA (en) | 2012-11-16 | 2013-11-15 | Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US9663474B2 (en) |
| EP (1) | EP2925729B1 (en) |
| JP (1) | JP6297055B2 (en) |
| KR (1) | KR102253773B1 (en) |
| CN (1) | CN105051018B (en) |
| AU (1) | AU2013346793B2 (en) |
| BR (1) | BR112015011036B1 (en) |
| CA (1) | CA2886635C (en) |
| CL (1) | CL2015001265A1 (en) |
| DK (1) | DK2925729T3 (en) |
| EA (1) | EA035431B1 (en) |
| ES (1) | ES2655843T3 (en) |
| IL (1) | IL237864A (en) |
| MX (1) | MX361585B (en) |
| MY (1) | MY171115A (en) |
| NZ (2) | NZ748345A (en) |
| PH (1) | PH12015500983B1 (en) |
| PL (1) | PL2925729T3 (en) |
| SG (1) | SG11201503042QA (en) |
| UA (1) | UA118341C2 (en) |
| WO (1) | WO2014076221A1 (en) |
Families Citing this family (165)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103608335B (en) | 2011-04-08 | 2018-02-23 | 爱尔兰詹森科学公司 | For treating the pyrimidine derivatives of virus infection |
| BR122019020718B1 (en) | 2011-11-09 | 2021-07-06 | Janssen Sciences Ireland Uc | PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND THE PHARMACEUTICAL COMPOSITION INCLUDING THEM |
| MX360718B (en) | 2012-07-13 | 2018-11-13 | Janssen Sciences Ireland Uc | Macrocyclic purines for the treatment of viral infections. |
| TR201807076T4 (en) | 2012-10-10 | 2018-06-21 | Janssen Sciences Ireland Uc | Pyrrolo [3,2-d] pyrimidine derivatives for the treatment of viral infections and other diseases. |
| SG11201503042QA (en) | 2012-11-16 | 2015-06-29 | Janssen Sciences Ireland Uc | Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections |
| EA035174B1 (en) | 2013-02-21 | 2020-05-12 | Янссен Сайенсиз Айрлэнд Юси | 2-aminopyrimidine derivatives as modulators of toll-like receptors tlr7 and/or tlr8 |
| HRP20170654T1 (en) | 2013-03-29 | 2017-06-30 | Janssen Sciences Ireland Uc | Macrocyclic deaza-purinones for the treatment of viral infections |
| DK3004074T3 (en) | 2013-05-24 | 2018-01-29 | Janssen Sciences Ireland Uc | PYRIDONE DERIVATIVES FOR TREATING VIRUS INFECTIONS AND ADDITIONAL DISEASES |
| HRP20171720T1 (en) | 2013-06-27 | 2017-12-29 | Janssen Sciences Ireland Uc | Pyrrolo [3,2-d] pyrimidine derivatives for the treatment of viral infections and other diseases |
| EP3027624B1 (en) | 2013-07-30 | 2018-09-12 | Janssen Sciences Ireland UC | Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections |
| EP3722297A1 (en) * | 2015-03-04 | 2020-10-14 | Gilead Sciences, Inc. | Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds |
| JP2018525412A (en) | 2015-08-26 | 2018-09-06 | ギリアード サイエンシーズ， インコーポレイテッド | Deuterated toll-like receptor modulator |
| JP2018527366A (en) | 2015-09-15 | 2018-09-20 | ギリアード サイエンシーズ， インコーポレイテッド | Toll-like receptor modulators for treating HIV |
| CN109311967B (en) | 2015-12-15 | 2022-03-04 | 吉利德科学公司 | human immunodeficiency virus neutralizing antibody |
| CN108473493B (en) * | 2016-01-07 | 2022-05-27 | 爱尔兰詹森科学公司 | Functionalized valeric acids for influenza virus infection |
| BR102017010009A2 (en) | 2016-05-27 | 2017-12-12 | Gilead Sciences, Inc. | COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION |
| AU2017271990B2 (en) | 2016-05-27 | 2019-12-19 | Gilead Sciences, Inc. | Methods for treating Hepatitis B virus infections using NS5A, NS5B or NS3 inhibitors |
| US11053256B2 (en) | 2016-07-01 | 2021-07-06 | Janssen Sciences Ireland Unlimited Company | Dihydropyranopyrimidines for the treatment of viral infections |
| JOP20190024A1 (en) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | Substituted pyrrolizine compounds and uses thereof |
| EP3507288B1 (en) | 2016-09-02 | 2020-08-26 | Gilead Sciences, Inc. | 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators |
| PT3507276T (en) | 2016-09-02 | 2022-01-11 | Gilead Sciences Inc | TOLL-TYPE RECEIVER MODULATING COMPOUNDS |
| MA46340A (en) | 2016-09-29 | 2019-08-07 | Janssen Sciences Ireland Unlimited Co | PYRIMIDINE MEDICINES FOR THE TREATMENT OF VIRAL INFECTIONS AND OTHER DISEASES |
| US10662416B2 (en) | 2016-10-14 | 2020-05-26 | Precision Biosciences, Inc. | Engineered meganucleases specific for recognition sequences in the hepatitis B virus genome |
| TW202510891A (en) | 2017-01-31 | 2025-03-16 | 美商基利科學股份有限公司 | Crystalline forms of tenofovir alafenamide |
| JOP20180008A1 (en) | 2017-02-02 | 2019-01-30 | Gilead Sciences Inc | Compounds for the treatment of hepatitis b virus infection |
| WO2018181420A1 (en) | 2017-03-29 | 2018-10-04 | 大日本住友製薬株式会社 | Vaccine adjuvant formulation |
| JOP20180040A1 (en) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | Pd-1/pd-l1 inhibitors |
| AR112412A1 (en) * | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | CHOLINE SALT FORMS OF AN HIV CAPSID INHIBITOR |
| AR112413A1 (en) * | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | SOLID FORMS OF AN HIV CAPSID INHIBITOR |
| KR102891807B1 (en) | 2017-08-22 | 2025-12-01 | 길리애드 사이언시즈, 인코포레이티드 | Therapeutic heterocyclic compounds |
| WO2019084060A1 (en) | 2017-10-24 | 2019-05-02 | Silverback Therapeutics, Inc. | Conjugates and methods of use thereof for selective delivery of immune-modulatory agents |
| JP2021506827A (en) | 2017-12-15 | 2021-02-22 | シルバーバック セラピューティックス インコーポレイテッド | Antibody constructs for the treatment of hepatitis-drug conjugates |
| US11203610B2 (en) | 2017-12-20 | 2021-12-21 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| CN111566120B (en) | 2017-12-20 | 2023-09-29 | 捷克共和国有机化学与生物化学研究所 | 3’3’ cyclic dinucleotide with phosphonate bond that activates STING adapter protein |
| CN109867627B (en) * | 2018-02-07 | 2021-05-07 | 南方医科大学 | A kind of substituted phenol β-amino alcohol derivative and its preparation method and use |
| CR20200347A (en) | 2018-02-13 | 2020-09-23 | Gilead Sciences Inc | Pd-1/pd-l1 inhibitors |
| US10836746B2 (en) | 2018-02-15 | 2020-11-17 | Gilead Sciences, Inc. | Therapeutic compounds |
| JP7038843B2 (en) | 2018-02-16 | 2022-03-18 | ギリアード サイエンシーズ， インコーポレイテッド | Methods and Intermediates for Preparing Therapeutic Compounds Useful in the Treatment of Retroviridae Virus Infections |
| US10836769B2 (en) | 2018-02-26 | 2020-11-17 | Gilead Sciences, Inc. | Substituted pyrrolizine compounds and uses thereof |
| TW202415645A (en) | 2018-03-01 | 2024-04-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | 2,4-diaminoquinazoline derivatives and medical uses thereof |
| US10870691B2 (en) | 2018-04-05 | 2020-12-22 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis B virus protein X |
| TWI818007B (en) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-cyclic dinucleotides |
| TWI833744B (en) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-cyclic dinucleotides |
| TW202005654A (en) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | 2'2'-cyclic dinucleotides |
| TW201945388A (en) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis B virus genome |
| KR102591947B1 (en) | 2018-04-19 | 2023-10-25 | 길리애드 사이언시즈, 인코포레이티드 | PD-1/PD-L1 inhibitors |
| WO2019211799A1 (en) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide |
| CR20200653A (en) | 2018-07-03 | 2021-02-11 | Gilead Sciences Inc | ANTIBODIES TARGETING HIV GP120 AND METHODS OF USE |
| CA3103987C (en) | 2018-07-06 | 2023-08-01 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
| US11186579B2 (en) | 2018-07-06 | 2021-11-30 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
| PT3820572T (en) | 2018-07-13 | 2023-11-10 | Gilead Sciences Inc | Pd-1/pd-l1 inhibitors |
| KR20230141905A (en) | 2018-07-16 | 2023-10-10 | 길리애드 사이언시즈, 인코포레이티드 | Capsid inhibitors for the treatment of hiv |
| PH12021550175A1 (en) | 2018-07-23 | 2022-07-11 | Japan As Represented By Director General Of Nat Institute Of Infectious Diseases | Composition containing influenza vaccine |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| SG11202101980VA (en) | 2018-09-12 | 2021-03-30 | Silverback Therapeutics Inc | Methods and composition for the treatment of disease with immune stimulatory conjugates |
| ES2999323T3 (en) | 2018-09-19 | 2025-02-25 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Tlr8 agonist |
| WO2020072656A1 (en) | 2018-10-03 | 2020-04-09 | Gilead Sciences, Inc. | Imidozopyrimidine derivatives |
| WO2020078455A1 (en) * | 2018-10-19 | 2020-04-23 | 南京明德新药研发有限公司 | Tlr8 agonist |
| JP7158577B2 (en) | 2018-10-24 | 2022-10-21 | ギリアード サイエンシーズ， インコーポレイテッド | PD-1/PD-L1 inhibitor |
| EP4371987B9 (en) | 2018-10-31 | 2025-11-26 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors |
| KR102658602B1 (en) | 2018-10-31 | 2024-04-19 | 길리애드 사이언시즈, 인코포레이티드 | Substituted 6-azabenzimidazole compounds with HPK1 inhibitory activity |
| JP7287708B2 (en) | 2019-02-08 | 2023-06-06 | プロジェニア インコーポレイテッド | Toll-like receptor 7 or 8 agonist-cholesterol conjugate and use thereof |
| WO2020176505A1 (en) | 2019-02-25 | 2020-09-03 | Gilead Sciences, Inc. | Protein kinase c agonists |
| WO2020176510A1 (en) | 2019-02-25 | 2020-09-03 | Gilead Sciences, Inc. | Protein kinase c agonists |
| CN113543851B (en) | 2019-03-07 | 2025-03-18 | 捷克共和国有机化学与生物化学研究所 | 2'3'-Cyclic dinucleotides and prodrugs thereof |
| US20220143061A1 (en) | 2019-03-07 | 2022-05-12 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| EP3935065A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| TW202544011A (en) | 2019-03-22 | 2025-11-16 | 美商基利科學股份有限公司 | Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use |
| TW202210480A (en) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | Solid forms of a toll-like receptor modulator |
| TWI751517B (en) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | Solid forms of a toll-like receptor modulator |
| TWI762925B (en) | 2019-05-21 | 2022-05-01 | 美商基利科學股份有限公司 | Methods of identifying hiv patients sensitive to therapy with gp120 v3 glycan-directed antibodies |
| WO2020237025A1 (en) | 2019-05-23 | 2020-11-26 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| CA3140708A1 (en) | 2019-06-18 | 2020-12-24 | Helen Horton | Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives |
| WO2020255039A1 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and quinazoline derivatives |
| WO2020257407A1 (en) | 2019-06-19 | 2020-12-24 | Silverback Therapeutics, Inc. | Anti-mesothelin antibodies and immunoconjugates thereof |
| WO2020263830A1 (en) | 2019-06-25 | 2020-12-30 | Gilead Sciences, Inc. | Flt3l-fc fusion proteins and methods of use |
| TWI879779B (en) | 2019-06-28 | 2025-04-11 | 美商基利科學股份有限公司 | Processes for preparing toll-like receptor modulator compounds |
| AU2020315598B2 (en) | 2019-07-16 | 2024-12-12 | Gilead Sciences, Inc. | HIV vaccines and methods of making and using |
| WO2021011891A1 (en) | 2019-07-18 | 2021-01-21 | Gilead Sciences, Inc. | Long-acting formulations of tenofovir alafenamide |
| EP4017476A1 (en) | 2019-08-19 | 2022-06-29 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| CA3149557A1 (en) | 2019-09-30 | 2021-04-08 | Scott J. Balsitis | Hbv vaccines and methods treating hbv |
| CA3151322A1 (en) | 2019-10-01 | 2021-04-08 | Silverback Therapeutics, Inc. | Combination therapy with immune stimulatory conjugates |
| CN118178645A (en) | 2019-10-18 | 2024-06-14 | 四十七公司 | Combination therapy for the treatment of myelodysplastic syndrome and acute myeloid leukemia |
| KR20220091576A (en) | 2019-10-31 | 2022-06-30 | 포티 세븐, 인코포레이티드 | Anti-CD47 and Anti-CD20 Based Treatment of Hematological Cancers |
| TWI778443B (en) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1 inhibitors |
| WO2021108544A1 (en) | 2019-11-26 | 2021-06-03 | Gilead Sciences, Inc. | Capsid inhibitors for the prevention of hiv |
| WO2021113765A1 (en) | 2019-12-06 | 2021-06-10 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
| HRP20241518T1 (en) | 2019-12-24 | 2025-01-03 | Carna Biosciences, Inc. | Diacylglycerol kinase modulating compounds |
| PH12022552122A1 (en) | 2020-02-14 | 2024-01-29 | Jounce Therapeutics Inc | Antibodies and fusion proteins that bind to ccr8 and uses thereof |
| WO2021168274A1 (en) | 2020-02-21 | 2021-08-26 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
| AU2021231160A1 (en) | 2020-03-02 | 2022-09-22 | Progeneer Inc. | Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof |
| US12516057B2 (en) * | 2020-03-18 | 2026-01-06 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd | Crystalline form of TLR8 agonist |
| AR121620A1 (en) | 2020-03-20 | 2022-06-22 | Gilead Sciences Inc | 4-C-SUBSTITUTED-2-HALO-2-DEOXIADENOSINE NUCLEOSIDE PRODRUGS AND METHODS OF PREPARATION AND USE THEREOF |
| US12110294B2 (en) | 2020-05-01 | 2024-10-08 | Gilead Sciences, Inc. | CD73 compounds |
| WO2021236944A1 (en) | 2020-05-21 | 2021-11-25 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising bictegravir |
| CA3181690A1 (en) | 2020-06-25 | 2021-12-30 | Chienhung CHOU | Capsid inhibitors for the treatment of hiv |
| KR20230047361A (en) | 2020-07-01 | 2023-04-07 | 아르스 파마슈티컬스 인크. | Anti-ASGR1 antibody conjugates and uses thereof |
| WO2022031021A1 (en) | 2020-08-04 | 2022-02-10 | 성균관대학교산학협력단 | Mrna vaccine comprising adjuvant capable of kinetic control |
| JP2023536954A (en) | 2020-08-04 | 2023-08-30 | プロジェニア インコーポレイテッド | Conjugate of Toll-like Receptor 7 or 8 Agonist with Temporarily Inactivated Activation Site and Functional Drug, and Use of the Same |
| EP4194008A4 (en) | 2020-08-04 | 2025-01-08 | Progeneer Inc. | KINETIC ACTION ADJUVANT SET |
| ES3054072T3 (en) | 2020-08-07 | 2026-01-29 | Gilead Sciences Inc | Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use |
| TWI815194B (en) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | INTERLEUKIN-2-Fc FUSION PROTEINS AND METHODS OF USE |
| US20220144923A1 (en) | 2020-11-11 | 2022-05-12 | Gilead Sciences, Inc. | METHODS OF IDENTIFYING HIV PATIENTS SENSITIVE TO THERAPY WITH gp120 CD4 BINDING SITE-DIRECTED ANTIBODIES |
| AU2022253902A1 (en) | 2021-04-10 | 2023-11-02 | Genmab A/S | Folr1 binding agents, conjugates thereof and methods of using the same |
| TW202302145A (en) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | Co-inhibition of cd47/sirpα binding and nedd8-activating enzyme e1 regulatory subunit for the treatment of cancer |
| JP7742892B2 (en) | 2021-04-23 | 2025-09-22 | ジェンマブ エー／エス | Anti-CD70 antibodies, conjugates thereof and methods of using same |
| JP2024518558A (en) | 2021-05-13 | 2024-05-01 | ギリアード サイエンシーズ， インコーポレイテッド | Combination of TLR8 Modulating Compounds with Anti-HBV siRNA Therapeutics |
| WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
| US11976072B2 (en) | 2021-06-23 | 2024-05-07 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| EP4359413A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| US11932634B2 (en) | 2021-06-23 | 2024-03-19 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| TW202320857A (en) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | Linkers, drug linkers and conjugates thereof and methods of using the same |
| US20230183216A1 (en) | 2021-10-28 | 2023-06-15 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| CR20240173A (en) | 2021-10-29 | 2024-06-20 | Gilead Sciences Inc | CD73 COMPOUNDS |
| CN118369316A (en) | 2021-12-03 | 2024-07-19 | 吉利德科学公司 | Therapeutic compounds for HIV infection |
| US12084467B2 (en) | 2021-12-03 | 2024-09-10 | Gilead Sciences, Inc. | Therapeutic compounds for HIV virus infection |
| PL4445900T3 (en) | 2021-12-03 | 2025-09-22 | Gilead Sciences, Inc. | THERAPEUTIC COMPOUNDS AGAINST HIV INFECTION |
| US20230203202A1 (en) | 2021-12-08 | 2023-06-29 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and 5t4 |
| WO2023107954A1 (en) | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Antibodies targeting 5t4 and uses thereof |
| JP2024546851A (en) | 2021-12-22 | 2024-12-26 | ギリアード サイエンシーズ， インコーポレイテッド | IKAROS ZINC FINGER FAMILY DEGRADANT AND USES THEREOF |
| CN118488948A (en) | 2021-12-22 | 2024-08-13 | 吉利德科学公司 | IKAROS zinc finger family degraders and their uses |
| TW202340168A (en) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Parp7 inhibitors |
| JP2025509610A (en) | 2022-03-17 | 2025-04-11 | ギリアード サイエンシーズ， インコーポレイテッド | IKAROS ZINC FINGER FAMILY DEGRADANT AND USES THEREOF |
| WO2023183817A1 (en) | 2022-03-24 | 2023-09-28 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TWI876305B (en) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | Combination therapy for treating colorectal cancer |
| TWI856796B (en) | 2022-04-06 | 2024-09-21 | 美商基利科學股份有限公司 | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| JP2025513258A (en) | 2022-04-21 | 2025-04-24 | ギリアード サイエンシーズ， インコーポレイテッド | KRA G12D modulating compounds |
| TWI867601B (en) | 2022-07-01 | 2024-12-21 | 美商基利科學股份有限公司 | Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection |
| IL317958A (en) | 2022-07-01 | 2025-02-01 | Gilead Sciences Inc | Cd73 compounds |
| AU2023307100A1 (en) | 2022-07-12 | 2025-01-02 | Gilead Sciences, Inc. | Hiv immunogenic polypeptides and vaccines and uses thereof |
| KR20250051732A (en) | 2022-08-26 | 2025-04-17 | 길리애드 사이언시즈, 인코포레이티드 | Dosage and schedule regimen for broadly neutralizing antibodies |
| US20240091351A1 (en) | 2022-09-21 | 2024-03-21 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY |
| EP4598934A1 (en) | 2022-10-04 | 2025-08-13 | Gilead Sciences, Inc. | 4'-thionucleoside analogues and their pharmaceutical use |
| KR20250122479A (en) | 2022-12-22 | 2025-08-13 | 길리애드 사이언시즈, 인코포레이티드 | PRMT5 inhibitors and uses thereof |
| CN120882725A (en) | 2023-04-11 | 2025-10-31 | 吉利德科学公司 | KRAS-regulated compounds |
| AR132464A1 (en) | 2023-04-19 | 2025-07-02 | Gilead Sciences Inc | CAPSID INHIBITOR DOSAGE REGIMEN |
| CN121079300A (en) | 2023-04-21 | 2025-12-05 | 吉利德科学公司 | PRMT5 inhibitors and their uses |
| TW202448483A (en) | 2023-05-31 | 2024-12-16 | 美商基利科學股份有限公司 | Therapeutic compounds for hiv |
| WO2024249573A1 (en) | 2023-05-31 | 2024-12-05 | Gilead Sciences, Inc. | Solid forms of compounds useful in the treatment of hiv |
| WO2025006720A1 (en) | 2023-06-30 | 2025-01-02 | Gilead Sciences, Inc. | Kras modulating compounds |
| WO2025024811A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025024663A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| AU2023460182A1 (en) | 2023-07-28 | 2026-02-05 | Gilead Sciences, Inc. | Weekly regimen of lenacapavir for the treatment and prevention of hiv |
| WO2025042394A1 (en) | 2023-08-23 | 2025-02-27 | Gilead Sciences, Inc. | Dosing regimen of hiv capsid inhibitor |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250101042A1 (en) | 2023-09-08 | 2025-03-27 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| AR133955A1 (en) | 2023-09-26 | 2025-11-19 | Profoundbio Us Co | PTK7 BINDING AGENTS, CONJUGATES THEREOF AND METHODS OF USE THEREOF |
| WO2025080879A1 (en) | 2023-10-11 | 2025-04-17 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| WO2025080863A1 (en) | 2023-10-11 | 2025-04-17 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| WO2025080850A1 (en) | 2023-10-11 | 2025-04-17 | Gilead Sciences, Inc. | Bridged tricyclic carbamoylpyridone compounds and uses thereof |
| WO2025096589A1 (en) | 2023-11-03 | 2025-05-08 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20250230163A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Solid forms of hiv integrase inhibitors |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025149661A1 (en) | 2024-01-10 | 2025-07-17 | Genmab A/S | Slitrk6 binding agents, conjugates thereof and methods of using the same |
| US20250381289A1 (en) | 2024-02-29 | 2025-12-18 | Genmab A/S | Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same |
| US20250333424A1 (en) | 2024-03-01 | 2025-10-30 | Gilead Sciences, Inc. | Antiviral compounds |
| WO2025184447A1 (en) | 2024-03-01 | 2025-09-04 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising hiv integrase inhibitors |
| US20250289822A1 (en) | 2024-03-01 | 2025-09-18 | Gilead Sciences, Inc. | Solid forms of hiv integrase inhibitors |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| US20250345390A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| US20250345389A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| US20250376484A1 (en) | 2024-05-21 | 2025-12-11 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20260007683A1 (en) | 2024-06-14 | 2026-01-08 | Gilead Sciences, Inc. | Pharmaceutical compositions comprising hiv integrase inhibitors |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2610889B2 (en) | 1987-09-03 | 1997-05-14 | 日本臓器製薬株式会社 | New crosslinked adenine derivatives |
| WO1995034311A1 (en) * | 1994-06-13 | 1995-12-21 | Merck & Co., Inc. | Piperazine compounds promote release of growth hormone |
| CA2230808C (en) | 1996-07-03 | 2006-08-15 | Japan Energy Corporation | A novel purine derivative |
| JP3621706B2 (en) | 1996-08-28 | 2005-02-16 | ファイザー・インク | Substituted 6,5-hetero-bicyclic derivatives |
| EP0989129B1 (en) | 1996-10-04 | 2002-12-11 | Kyorin Pharmaceutical Co., Ltd. | Pyrazolopyridylpyridazinone derivatives and process for the preparation thereof |
| AR012634A1 (en) | 1997-05-02 | 2000-11-08 | Sugen Inc | QUINAZOLINE BASED COMPOUND, FAMACEUTICAL COMPOSITION THAT UNDERSTANDS IT, METHOD TO SYNTHESIZE IT, ITS USE, METHODS OF MODULATION OF THE DESERINE / TREONIN PROTEIN-KINASE FUNCTION AND IN VITRO METHOD TO IDENTIFY COMPOUNDS THAT MODULATE |
| US6339089B2 (en) | 1997-08-13 | 2002-01-15 | Fujirebio Inc. | Pyrimidine nucleus-containing compound and a medicament containing the same for a blood oxygen partial pressure amelioration, and a method for preparing the same |
| US6329381B1 (en) | 1997-11-28 | 2001-12-11 | Sumitomo Pharmaceuticals Company, Limited | Heterocyclic compounds |
| TW572758B (en) | 1997-12-22 | 2004-01-21 | Sumitomo Pharma | Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives |
| US6187777B1 (en) | 1998-02-06 | 2001-02-13 | Amgen Inc. | Compounds and methods which modulate feeding behavior and related diseases |
| IL137922A0 (en) | 1998-02-17 | 2001-10-31 | Tularik Inc | Anti-viral pyrimidine derivatives |
| US6110929A (en) | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
| JP4342007B2 (en) * | 1998-08-10 | 2009-10-14 | 大日本住友製薬株式会社 | Quinazoline derivatives |
| JP4315300B2 (en) | 1998-08-10 | 2009-08-19 | 大日本住友製薬株式会社 | Novel quinazoline derivatives |
| CA2341707C (en) | 1998-08-27 | 2010-02-16 | Sumitomo Pharmaceuticals Co., Ltd. | Pyrimidine derivatives |
| US6583148B1 (en) | 1999-04-08 | 2003-06-24 | Krenitsky Pharmaceuticals, Inc. | Neurotrophic substituted pyrimidines |
| US6503908B1 (en) | 1999-10-11 | 2003-01-07 | Pfizer Inc | Pharmaceutically active compounds |
| US7074801B1 (en) * | 2001-04-26 | 2006-07-11 | Eisai Co., Ltd. | Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof |
| WO2002088079A2 (en) | 2001-05-01 | 2002-11-07 | Bristol-Myers Squibb Company | Dual inhibitors of pde 7 and pde 4 |
| WO2003055890A1 (en) | 2001-12-21 | 2003-07-10 | Bayer Pharmaceuticals Corporation | Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
| TW200407143A (en) | 2002-05-21 | 2004-05-16 | Bristol Myers Squibb Co | Pyrrolotriazinone compounds and their use to treat diseases |
| US7091232B2 (en) | 2002-05-21 | 2006-08-15 | Allergan, Inc. | 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds |
| WO2003104230A1 (en) | 2002-06-07 | 2003-12-18 | 協和醱酵工業株式会社 | Bicyclic pyrimidine derivatives |
| MXPA05003193A (en) | 2002-09-27 | 2005-06-08 | Sumitomo Pharma | Novel adenine compound and use thereof. |
| US8455458B2 (en) | 2002-10-16 | 2013-06-04 | Arthrodynamic Technologies, Animal Health Division, Inc. | Composition and method for treating connective tissue damage |
| US7410975B2 (en) | 2003-06-20 | 2008-08-12 | Coley Pharmaceutical Group, Inc. | Small molecule toll-like receptor (TLR) antagonists |
| US7576068B2 (en) | 2003-09-05 | 2009-08-18 | Anadys Pharmaceuticals, Inc. | Administration of TLR7 ligands and prodrugs thereof for treatment of infection by hepatitis C virus |
| CA2559036C (en) | 2004-03-26 | 2013-08-20 | Dainippon Sumitomo Pharma Co., Ltd. | 9-substituted 8-oxoadenine compound |
| US20070225303A1 (en) | 2004-03-26 | 2007-09-27 | Haruhisa Ogita | 8-Oxoadenine Compound |
| WO2007084413A2 (en) | 2004-07-14 | 2007-07-26 | Ptc Therapeutics, Inc. | Methods for treating hepatitis c |
| JP5031564B2 (en) | 2004-08-10 | 2012-09-19 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | HIV-inhibited 1,2,4-triazin-6-one derivative |
| BRPI0517559A (en) | 2004-11-09 | 2008-10-14 | Hoffmann La Roche | compound, process for its preparation, method for the therapeutic and / or prophylactic treatment of diseases that are modulated by ptb-1b inhibitors and use of the compounds |
| US7498409B2 (en) | 2005-03-24 | 2009-03-03 | Schering Corporation | Screening assay for TLR7, TLR8 and TLR9 agonists and antagonists |
| MX2007013780A (en) | 2005-05-04 | 2008-02-05 | Pfizer Ltd | 2-amido-6-amino-8-oxopurine derivatives as toll-like receptor modulators for the treatment of cancer and viral infections, such as hepatitis c. |
| TW200716631A (en) | 2005-05-12 | 2007-05-01 | Tibotec Pharm Ltd | Pyrido[2,3-d]pyrimidines useful as HCV inhibitors, and methods for the preparation thereof |
| US7994360B2 (en) | 2005-05-16 | 2011-08-09 | Xtl Biopharmaceuticals Ltd. | Benzofuran compounds |
| EP1924564B1 (en) | 2005-09-01 | 2016-11-09 | F.Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
| WO2007034881A1 (en) | 2005-09-22 | 2007-03-29 | Dainippon Sumitomo Pharma Co., Ltd. | Novel adenine compound |
| WO2007056208A2 (en) | 2005-11-02 | 2007-05-18 | Cytovia, Inc. | N-arylalkyl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| US20090182140A1 (en) | 2005-12-02 | 2009-07-16 | Mitsubishi Tanabe Pharma Corporation | Alicyclic Heterocyclic Compound |
| KR20080085232A (en) | 2006-02-17 | 2008-09-23 | 화이자 리미티드 | 3-deazapurine derivatives as TLR7 modulators |
| US9259426B2 (en) | 2006-07-20 | 2016-02-16 | Gilead Sciences, Inc. | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections |
| WO2008009077A2 (en) | 2006-07-20 | 2008-01-24 | Gilead Sciences, Inc. | 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections |
| BRPI0717907A2 (en) | 2006-12-07 | 2013-11-05 | Genentech Inc | "COMPOUND, PHARMACEUTICAL COMPOSITION, METHODS FOR TREATING A CANCER, INHIBITING OR MODULATING LIPID KINASE ACTIVITY, PROCESS FOR PRODUCING PHARMACEUTICAL COMPOSITION, USE OF A COMPOUND AND KIT" |
| CN103224506A (en) | 2006-12-20 | 2013-07-31 | P.安杰莱蒂分子生物学研究所 | Antiviral indoles |
| PT2510946E (en) | 2007-02-07 | 2015-11-23 | Univ California | Conjugates of synthetic tlr agonists and uses therefor |
| JP2008222557A (en) | 2007-03-08 | 2008-09-25 | Kotobuki Seiyaku Kk | PYRROLO[3,2-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS EFFECTIVE COMPONENT |
| JP5480637B2 (en) | 2007-03-19 | 2014-04-23 | アストラゼネカ・アクチエボラーグ | 9-Substituted-8-oxo-adenine compounds as TOLL-like receptor (TLR7) modulators |
| JPWO2008114819A1 (en) | 2007-03-20 | 2010-07-08 | 大日本住友製薬株式会社 | New adenine compounds |
| PE20081887A1 (en) | 2007-03-20 | 2009-01-16 | Dainippon Sumitomo Pharma Co | NEW ADENINE COMPOUND |
| EP2152674B1 (en) | 2007-05-22 | 2011-08-03 | Boehringer Ingelheim International GmbH | Benzimidazolone chymase inhibitors |
| TWI434849B (en) | 2007-06-29 | 2014-04-21 | Gilead Sciences Inc | Modulators of toll-like receptor 7 |
| WO2009023179A2 (en) | 2007-08-10 | 2009-02-19 | Genelabs Technologies, Inc. | Nitrogen containing bicyclic chemical entities for treating viral infections |
| WO2009032668A2 (en) | 2007-08-28 | 2009-03-12 | Irm Llc | 2 -biphenylamino-4 -aminopyrimidine derivatives as kinase inhibitors |
| WO2009030998A1 (en) | 2007-09-05 | 2009-03-12 | Coley Pharmaceutical Group, Inc. | Pyrimidine compounds as toll-like receptor (tlr) agonists |
| PE20091236A1 (en) | 2007-11-22 | 2009-09-16 | Astrazeneca Ab | PYRIMIDINE DERIVATIVES AS IMMUNOMODULATORS OF TLR7 |
| DK2238142T3 (en) | 2007-12-24 | 2012-10-08 | Janssen R & D Ireland | Macrocyclic indoles such as hepatitis C virus inhibitors |
| CN102088974A (en) | 2008-02-07 | 2011-06-08 | 加利福尼亚大学校务委员会 | Treatment of bladder disease with TLR7 activators |
| CA2720850A1 (en) | 2008-04-28 | 2009-11-05 | Merck Sharp & Dohme Corp. | Hcv ns3 protease inhibitors |
| US8946239B2 (en) | 2008-07-10 | 2015-02-03 | Duquesne University Of The Holy Spirit | Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof |
| UY31982A (en) | 2008-07-16 | 2010-02-26 | Boehringer Ingelheim Int | DERIVATIVES OF 1,2-DIHYDROPIRIDIN-3-CARBOXAMIDS N-SUBSTITUTED |
| MX2011012337A (en) | 2009-05-21 | 2011-12-08 | Dainippon Sumitomo Pharma Co | Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases. |
| US8637525B2 (en) | 2009-07-31 | 2014-01-28 | Bristol-Myers Squibb Company | Compounds for the reduction of beta-amyloid production |
| TWI468402B (en) | 2009-07-31 | 2015-01-11 | 必治妥美雅史谷比公司 | Compounds for the reduction of β-amyloid production |
| US20120232062A1 (en) | 2009-10-20 | 2012-09-13 | Eiger Biopharmaceuticals, Inc. | Azaindazoles to treat flaviviridae virus infection |
| CN102666541B (en) | 2009-10-22 | 2015-11-25 | 吉里德科学公司 | Derivatives of purines or deazapurines for use in the treatment, especially of viral infections |
| KR101094446B1 (en) | 2009-11-19 | 2011-12-15 | 한국과학기술연구원 | 2,4,7-substituted thieno [3,2-d] pyrimidine compounds with protein kinase inhibitory activity |
| JP2013032290A (en) | 2009-11-20 | 2013-02-14 | Dainippon Sumitomo Pharma Co Ltd | Novel fused pyrimidine derivative |
| DE102010040233A1 (en) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclic aza heterocycles and their use |
| WO2012066335A1 (en) | 2010-11-19 | 2012-05-24 | Astrazeneca Ab | Phenol compounds als toll -like receptor 7 agonists |
| WO2012067269A1 (en) | 2010-11-19 | 2012-05-24 | Dainippon Sumitomo Pharma Co., Ltd. | Aminoalkoxyphenyl compounds and their use in the treatment of disease |
| WO2012079079A1 (en) * | 2010-12-10 | 2012-06-14 | President And Fellows Of Harvard College | Production of induced pluripotent stem cells |
| CN103608335B (en) | 2011-04-08 | 2018-02-23 | 爱尔兰詹森科学公司 | For treating the pyrimidine derivatives of virus infection |
| EA028254B1 (en) | 2011-05-18 | 2017-10-31 | Янссен Сайенсиз Айрлэнд Юси | Quinazoline derivatives for the treatment of viral infections and further diseases |
| BR122019020718B1 (en) | 2011-11-09 | 2021-07-06 | Janssen Sciences Ireland Uc | PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND THE PHARMACEUTICAL COMPOSITION INCLUDING THEM |
| CN104245695B (en) | 2012-02-08 | 2017-06-06 | 爱尔兰詹森科学公司 | Piperidinyl pyrimidine derivatives for treating viral infection |
| MX371331B (en) | 2012-04-24 | 2020-01-27 | Vertex Pharma | Dna-pk inhibitors. |
| MX360718B (en) | 2012-07-13 | 2018-11-13 | Janssen Sciences Ireland Uc | Macrocyclic purines for the treatment of viral infections. |
| CN104781239B (en) | 2012-08-10 | 2019-03-01 | 爱尔兰詹森科学公司 | Alkylpyrimidine derivatives for the treatment of viral infections and other diseases |
| EP2712866A1 (en) | 2012-10-01 | 2014-04-02 | Centre National de la Recherche Scientifique (CNRS) | 1,2,4-triazine derivatives for the treatment of viral infections |
| EA034650B1 (en) | 2012-10-05 | 2020-03-03 | Янссен Сайенсиз Айрлэнд Юси | Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases |
| TR201807076T4 (en) | 2012-10-10 | 2018-06-21 | Janssen Sciences Ireland Uc | Pyrrolo [3,2-d] pyrimidine derivatives for the treatment of viral infections and other diseases. |
| SG11201503042QA (en) | 2012-11-16 | 2015-06-29 | Janssen Sciences Ireland Uc | Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections |
| EA035174B1 (en) | 2013-02-21 | 2020-05-12 | Янссен Сайенсиз Айрлэнд Юси | 2-aminopyrimidine derivatives as modulators of toll-like receptors tlr7 and/or tlr8 |
| HRP20170654T1 (en) | 2013-03-29 | 2017-06-30 | Janssen Sciences Ireland Uc | Macrocyclic deaza-purinones for the treatment of viral infections |
| EP3027624B1 (en) | 2013-07-30 | 2018-09-12 | Janssen Sciences Ireland UC | Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections |
| US9701661B2 (en) | 2014-07-11 | 2017-07-11 | Northwestern University | 2-imidazolyl-pyrimidine scaffolds as potent and selective inhibitors of neuronal nitric oxide synthase |
-
2013
- 2013-11-15 SG SG11201503042QA patent/SG11201503042QA/en unknown
- 2013-11-15 CN CN201380059827.3A patent/CN105051018B/en not_active Expired - Fee Related
- 2013-11-15 EA EA201590931A patent/EA035431B1/en unknown
- 2013-11-15 KR KR1020157010310A patent/KR102253773B1/en not_active Expired - Fee Related
- 2013-11-15 CA CA2886635A patent/CA2886635C/en active Active
- 2013-11-15 US US14/443,305 patent/US9663474B2/en not_active Expired - Fee Related
- 2013-11-15 WO PCT/EP2013/073901 patent/WO2014076221A1/en not_active Ceased
- 2013-11-15 AU AU2013346793A patent/AU2013346793B2/en not_active Ceased
- 2013-11-15 MX MX2015006197A patent/MX361585B/en active IP Right Grant
- 2013-11-15 UA UAA201505893A patent/UA118341C2/en unknown
- 2013-11-15 NZ NZ748345A patent/NZ748345A/en not_active IP Right Cessation
- 2013-11-15 BR BR112015011036-3A patent/BR112015011036B1/en not_active IP Right Cessation
- 2013-11-15 JP JP2015542270A patent/JP6297055B2/en not_active Expired - Fee Related
- 2013-11-15 PL PL13789821T patent/PL2925729T3/en unknown
- 2013-11-15 NZ NZ70622613A patent/NZ706226A/en not_active IP Right Cessation
- 2013-11-15 DK DK13789821.9T patent/DK2925729T3/en active
- 2013-11-15 EP EP13789821.9A patent/EP2925729B1/en active Active
- 2013-11-15 MY MYPI2015001303A patent/MY171115A/en unknown
- 2013-11-15 ES ES13789821.9T patent/ES2655843T3/en active Active
-
2015
- 2015-03-22 IL IL237864A patent/IL237864A/en active IP Right Grant
- 2015-05-04 PH PH12015500983A patent/PH12015500983B1/en unknown
- 2015-05-11 CL CL2015001265A patent/CL2015001265A1/en unknown
-
2017
- 2017-05-10 US US15/591,473 patent/US10253003B2/en active Active
-
2019
- 2019-04-08 US US16/377,752 patent/US10723707B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201503042QA (en) | Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections | |
| ZA201405820B (en) | Piperidino-pyrimidine derivatives for the treatment of viral infections | |
| ZA201500921B (en) | Alkylpyrimidine derivatives for the treatment of viral infections and further diaseases | |
| ZA201501018B (en) | Compounds for the treatment of paramoxyvirus viral infections | |
| ZA201307472B (en) | Pyrimidine derivatives for the treatment of viral infections | |
| IL239859A0 (en) | 2-aminopyrimidine derivatives for the treatment of viral infections | |
| SI2943493T1 (en) | Therapeutic compounds for the treatment of viral infections | |
| AP2015008968A0 (en) | Glyoxamide substituted pyrrolamide derivatives andthe use thereof as medicaments for the treatment of hepatitis b | |
| IL235990A0 (en) | Macrocyclic purines for the treatment of viral infections | |
| PH12014501045A1 (en) | Purine derivatives for the treatment of viral infections | |
| ZA201502238B (en) | Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases |